Close

XTL Biopharma (XTLB) Announces Receipt of NASDAQ Notification Regarding Minimum Bid Requirements

Go back to XTL Biopharma (XTLB) Announces Receipt of NASDAQ Notification Regarding Minimum Bid Requirements

XTL Biopharmaceuticals Receives NASDAQ Notification Regarding Minimum Bid Requirements

November 9, 2016 1:25 PM EST

RAANANA, Israel, November 9, 2016 /PRNewswire/ --

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing its lead product for the treatment of autoimmune diseases, today announced that it received a notice from The NASDAQ Stock Market ("NASDAQ") that the Company is not in compliance with NASDAQ's Listing Rule 5450(a)(1) because the minimum bid price of the Company's American Depositary Shares ("ADSs") has closed below US$1.00 per share for 30 consecutive business days. The notification of... More